Typhoid Vi Polysaccharide Vaccine Market Size & Forecast 2033

The new report published by The Business Research Company, titled ""Typhoid Vi Polysaccharide Vaccine Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the typhoid vi polysaccharide vaccine market size has grown rapidly in recent years. It will grow from $4.98 billion in 2023 to $5.84 billion in 2024 at a compound annual growth rate (CAGR) of 17.3%. The typhoid vi polysaccharide vaccine market size is expected to see rapid growth in the next few years. It will grow to $11.28 billion in 2028 at a compound annual growth rate (CAGR) of 17.9%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Escalating Typhoid Prevalence Fuels Expansion In The Typhoid Vi Polysaccharide Vaccine Market
Rising typhoid prevalence is expected to propel the growth of the typhoid VI polysaccharide vaccine market going forward. Typhoid is an infection caused by the bacteria Salmonella typhi that can be fatal. It usually spreads through contaminated food or drink. Typhoid Vi polysaccharide vaccine is used to immunise adults and children aged 2 and up against typhoid fever caused by Salmonella enterica serovar Typhi, S. Typhi. For instance, in March 2021, according to a report shared by the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, infections with Salmonella Typhi were believed to affect 5,700 Americans annually, with 620 of these likely to require hospitalization. Typhoid fever mostly causes between 11 and 21 million cases worldwide every year, along with 200,000 fatalities. Therefore, the rising typhoid prevalence is driving the growth of the typhoid Vi polysaccharide vaccine market.

International Vaccine Institute's Dynamic Partnerships With Moderna And Gsk Fuel Advances In Typhoid Vi Polysaccharide Vaccine Market
Strategic partnerships are a key trend gaining popularity in the typhoid Vi polysaccharide vaccine market. Major companies operating in the typhoid Vi polysaccharide vaccine market are entering into partnerships to strengthen their position in the typhoid Vi polysaccharide market. For instance, in July 2022, The International Vaccine Institute, a South Korea-based international organization focused on infectious diseases of global health importance such as cholera, typhoid, shigella, and salmonella, partnered with Moderna, a US-based biopharmaceutical company. This partnership led to the world's first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine.

The typhoid vi polysaccharide vaccine market covered in this report is segmented -

1) By Type: Child, Adult
2) By Route of Administration: Oral, Parenteral
3) By Application: Government Institution, Private Sector, Other Applications

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=8313&type=discount

Major companies operating in the typhoid vi polysaccharide vaccine market report are Sanofi Pasteur SA, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Mylan NV, Serum Institute of India Pvt. Ltd., Biological E. Limited, Panacea Biotec Ltd., Shantha Biotechnics Pvt. Ltd., Cadila Healthcare Ltd., Merck Sharp & Dohme Corp., AstraZeneca Limited, Boryung Pharmaceutical Co., Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

Contents of the report:
1. Executive Summary
2. Typhoid Vi Polysaccharide Vaccine Market Report Structure
3. Typhoid Vi Polysaccharide Vaccine Market Trends And Strategies
4. Typhoid Vi Polysaccharide Vaccine Market - Macro Economic Scenario
5. Typhoid Vi Polysaccharide Vaccine Market Size And Growth
…..
27. Typhoid Vi Polysaccharide Vaccine Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.